The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions - Report - MDSpire
Advertisement
The effectiveness and safety of oral Chinese patent medicines in treating myocardial infarction complicated with heart failure: a network meta-analysis of 12 interventions
Clinical Report: Efficacy and Safety of Oral Chinese Patent Medicines for MI-HF
Overview
This network meta-analysis evaluates the effectiveness of oral Chinese patent medicines (CPMs) combined with conventional treatment for myocardial infarction with heart failure (MI-HF). The findings indicate that specific CPMs significantly improve cardiac function and exercise tolerance, although safety reporting remains limited.
Background
Myocardial infarction with heart failure (MI-HF) is a critical condition that significantly increases morbidity and mortality rates. The integration of oral Chinese patent medicines (CPMs) into treatment regimens represents a potential adjunctive therapy to conventional treatments. Understanding the efficacy of these CPMs is essential for optimizing patient outcomes in this high-risk population.
Data Highlights
CPM
Effectiveness
Yixinshu capsules
Best for total clinical effective rate
Xintong oral liquid
Best for improving LVEF and reducing LVESD
Shexiang Baoxin pill
Optimal for reducing LVEDD
Guanxin Shutong capsules
Most effective for lowering NT-proBNP and increasing 6 MWT distance
Key Findings
42 RCTs were included in the analysis, evaluating 12 oral CPMs.
Yixinshu capsules showed the highest total clinical effective rate.
Xintong oral liquid was most effective in improving left ventricular ejection fraction (LVEF).
Shexiang Baoxin pill was optimal for reducing left ventricular end-diastolic diameter (LVEDD).
Guanxin Shutong capsules effectively lowered NT-proBNP levels and increased the 6-minute walk test distance.
Short-term tolerability of CPMs was favorable, but safety reporting was inadequate.
Clinical Implications
The findings suggest that integrating specific oral CPMs into treatment regimens for MI-HF may enhance cardiac function and patient exercise capacity. However, clinicians should remain cautious regarding the limited safety data and consider these therapies as adjuncts to established treatment protocols.
Conclusion
Oral Chinese patent medicines show promise in improving outcomes for patients with myocardial infarction and heart failure, but further research is needed to confirm their safety and efficacy in larger, well-designed trials.
